Tysabri To Be Priced 20% Higher Than When Initially Launched
Biogen CFO predicts favorable reimbursement for natalizumab, minimizing cost for most patients.
Biogen CFO predicts favorable reimbursement for natalizumab, minimizing cost for most patients.